CareDx : ESG Report (CareDx 2026 ESG Report)

Published: 2026-04-29 11:57:14 ET CDNA

Published on 04/29/2026 at 11:57 am EDT

CareDx 2025 Environmental, Social, and Governance

Report

01 Message from the Company's Management

06 Social Impact

Education and Training

02 ESG Decision-Making and Strategy

Conference Participation & Support

2025 ESG Scorecard

Company Sponsored Clinical Trials & Studies

Supplier Social and Environmental Assessment

03 Company Profile

Customer/Patient Health and Safety

Products and Services

Cybersecurity and Privacy

Partnerships

Product Safety

Financial Performance

07 Our Employees

04 Our ESG Approach

Employee Benefits

About the ESG Report

Employee Health and Safety

Our Key Stakeholder Groups

Employee Training

- Our Stakeholders Are Our Business

Materiality Assessment 12

Key ESG Topics 13

United Nations Sustainable Development Goals 13

Policies for a Responsible Practice 15

Risk Management 16

Code of Business Conduct and Ethics 16

Anti-bribery, Anti-corruption Policy 17

Anti-competitive, Antitrust & Monopoly Practices 17

Environmental Initiatives 28

A Message from the Company's Management

Dear CareDx Stockholder,

2025 marked another important year of progress for CareDx as we continued to execute in line with our long-term strategy, which was outlined at our October 2024 Investor Day, and advance our mission to create life-changing solutions that enable transplant patients to thrive.

Building on the strategic framework shared with investors, we remained focused on disciplined execution, responsible growth, and strengthening the foundation of our business for long-term value creation. These priorities guide not

only our financial performance, but also how we operate, serve the transplant community, engage our employees, and uphold strong governance as a public company.

I am proud of the commitment our teams demonstrate every day and grateful for the continued support of our stockholders. We believe sustained performance is inseparable from a culture of integrity, accountability, and a long-term view of our role within the healthcare ecosystem.

Together, we remain focused on advancing our vision of a world where every patient receives the transplant they need to live longer, fuller lives.

Sincerely,

John W. Hanna, President and CEO

John W. Hanna

President and CEO

ESG Decision-Making and Strategy

We are honored to highlight the impact our business has had across the community and demonstrate our commitment

to a more sustainable future. We are committed to measuring the annual impact of our work and will continually develop environmental and social indicators to meet that need.

Governance will remain adaptable and ensure that the interest of all stakeholders is reflected in our business.

This report covers annual performance, ESG strategy and targets, and includes work, commitments, and initiatives that support

our employees, suppliers, and customers across our communities. It provides a progress report on ESG performance in a relevant and transparent way.

Environmental

United States energy consumption

2,332,008.7 KWh

Australia energy consumption

11,265.0 KWh

Sweden energy consumption

373,479.0 KWh

Total energy consumption

2,716,752.7 KWh

United States GHG emissions due to energy consumption (Scope 2)

526.1 Metric Tons CO2

Australia GHG emissions due to energy consumption (Scope 2) CO2

5.6 tonnes

Sweden GHG emissions due to energy consumption (Scope 2) CO2

6.7 tonnes

Total GHG emissions due to energy consumption (Scope 1 and 2)

538.4 Metric Tons CO2

United States water consumption

714,538 gallons

Australia water consumption

17,699.5 gallons

Sweden water consumption

116,024.3 gallons

Total water consumption

848,261.8 gallons

Social

Total number of employees

765

% of women employees

60%

Total number of new hires

283

% of women new hires

62%

Average hours of training per employee per year

Average hours of training per manager per year

Number of work-related injuries

11 workers' comp claims filed

Number of discrimination incidents reported

Governance

Revenue

$380 million

Adjusted EBITDA*

$32 million

Number of Board Members**

% of Women on the Board**

20%

Number of Board Committees

Number of Executive Team Members

Number of confirmed incidents of corruption

Number of confirmed incidents of non-compliance to anti-competitive laws and regulations

Number of Key ESG Topics Identified

Number of UN Sustainable Development Goals supported

* Non-GAAP Financial Measure. See Earnings Press Release, dated February 24, 2026, for a reconciliation of GAAP to Non-GAAP Financial Measures. 5

** As of April 15, 2026.

Company Prokle

CareDx, Inc. - The Transplant Company™ is a leading precision medicine solutions company focused on the discovery, development, and commercialization

of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. The Company's integrated solutions include non-invasive molecular testing for heart, kidney, and lung transplants; laboratory products; digital health technologies; and patient solutions that support care before and after transplant.

CareDx is the leading provider of genomics-based information for transplant patients. The company headquarters are in Brisbane, CA. CareDx serves the rest of the world through a presence across three continents. In the U.S., the company

has offices in Flowood, MS, Slidell, LA, Columbus, OH, West Chester, PA, and Omaha, NE. Globally, the company has offices in Sweden and Australia. Some regions are also served through our network of specialized distributors. We are committed

to producing an annual sustainability report encompassing the activities, policies and practices of all of our entities.

We offer a range of products and services for patients and caregivers throughout the transplant patient journey. The company's founding was based on our non-invasive surveillance test, AlloMap® Heart, for heart transplant patients. In the intervening years the company has significantly increased its product offerings to include AlloSure® Heart, AlloSure® Kidney, and AlloSure Lung, as well as specialized transplant pharmacy services, and digital transplant solutions that help transplant centers with patient management, outcomes quality, and operational support. We also offer Lab Products for pre- and

post-transplant applications, and solutions for stem cell transplantation and cell therapy.

For more details about our products and services, visit caredx.com.

Testing Services

Patient and Digital Solutions

Lab Products

Cell Transplant Therapy and Pharma Services

Leading provider of non-invasive surveillance tests to identify graft injury and assess immune status to help rule out rejection

Comprehensive transplant administration software and patient-focused applications and services

Next-generation genetic matching solutions for

pre-transplant HLA matching as well as innovative

kit-based post-transplant surveillance products

Assays to help accelerate clinical development for biopharma partners

Collaboration is a critical value we work to espouse across all our lines of business, and we are committed to creating life-changing solutions that enable transplant patients to thrive. As part of this mission, we continuously foster strategic partnerships and alliances with global medical institutions, hospital ecosystems, and biopharmaceutical and technical platform companies.

Global Medical Institutions

Hospital Ecosystems

Biopharmaceutical and Technical Platform Companies

Financial Performance

Revenue - Million $

2024

2025

Annual

333.8

380

Testing Services

249.4

274.5

Lab Products

40.8

48.4

Patient & Digital Solutions

43.6

56.9

Net Income (Loss) - Million $

52.5

(21.4)

Adjusted EBITDA Gain (Loss) - Million $

27.8

Key Financial Data (2024-2025)

Our ESG Approach

from key stakeholder groups. These stakeholders include patients, customers, shareholders, employees, proxy advisors, suppliers, and distributors. Our approach is outlined below.

01 Understand, identify, and compliance with current ESG standards and reporting frameworks.

03 and alignment processes. This process has provided insight which has led to alteration on pay, supermajority voting and other governance issues for our annual proxy process.

Further enhance our understanding of relevant ESG topics, risks, and opportunities through formal analysis with ESG partners.

Use gap analysis insights to improve disclosures and policies related to ESG and Sustainability standards and frameworks.

This is CareDx's third ESG report, designed to demonstrate and communicate with its stakeholders and shareholders its commitment to sustainable development and ultimately meet their expectations and interests in a transparent way. The content of the report corresponds to data covering the period from 1st January 2025 to 31st December 2025 and adheres to the principles of the Global Reporting Initiative (GRI) "Referenced" option.

For any further queries you may contact us at the following:

+ CareDx Inc., 8000 Marina Boulevard, 4th Floor, Brisbane, CA 94005-1021

+ Or email Natasha Wagner [email protected]

We recognize the importance of all stakeholder groups, whether these are internal stakeholders such as employees, or external stakeholders such as shareholders, patients, and our supply chain network. CareDx's main stakeholder groups are illustrated below as their impact is essential to our business.

Patients and Consumers

Employees

Healthcare Professionals and Organizations

Supply Chain Network

Stockholders

Government Entities

CareDx Key Stakeholder Groups

We engage with our patients through our patient ambassador program, educational webinars, live events, patient advocacy groups, sponsorships of specific initiatives, co-branded webinars, transplant patient caregivers' emails, patient guides, Patient Care Management (PCM) engagement with patients (via phone), and sponsoring industry conferences as well as regional and national advisory boards. We also work directly with patients to answer billing questions and to schedule in-home phlebotomy testing services. Patients are at the core of our mission, and regularly during the company's townhall meetings, a patient is invited to attend and share their personal story and how our products have made a difference in their journey.

to understanding their needs. CareDx engages with its employees through its intranet and through weekly meetings with managers, townhall meetings and events, quarterly earnings reports and calls, as well as regularly sharing progress against plan. We conduct an annual start of the year meeting to ensure understanding of business strategies and priorities for the year.

Attracting new talent and employee retention and satisfaction are key goals of our employee engagement strategy. We engage with prospective employees through social media posts such as on LinkedIn, and X (formerly known as Twitter). We also deploy employee retention initiatives including recognition tools such as Spot Awards and Kazoo points. To support our employees' professional development, we have invested in building what is now a maturing performance management process to enable individual growth and learning and development opportunities through LinkedIn Learning.

We also have a women's leadership group called the Women's Empowerment Community Alliance Network (WECAN). The purpose of this network is to provide like-minded women and their colleagues with a community of employees who support each other to navigate daily challenges, encourage empowerment, and promote personal and professional development to advance leadership and networking skills for continued industry success. The network is composed of four pillars: mentorship, networking, volunteerism, and allyship.

Providers, both individual physicians and hospitals/physician groups, are the tangible connection to transplant patients and are the key partners in helping us achieve our mission of creating life-changing solutions that enable transplant patients to thrive. Regular engagement with our providers is essential to aligning the strategic direction of CareDx with the innovations and services that will have the biggest impact on patient outcomes and sustainable transplant industry success. We engage with our providers to both receive feedback and input and to share best practices.

We do this through hosting local and national advisory boards, conducting webinars and site visits, presenting at and sponsoring industry conferences, industry workshops, and sponsoring clinical studies, principal investigator meetings, and steering committee meetings. We also share the latest information through peer-reviewed publications, advertising, and social media. Additionally, we regularly engage with our network of transplant clinicians and allied health professionals through

in-person visits by our field personnel (e.g., Medical Science Liaisons, Regional Directors and Territory Account Managers, Clinical Liasions and Patient Liaisons) and through emails, webinars, professional conferences, educational workshops, and peer to peer events.

We periodically assess our policies and procedures to improve consistency across interactions and engagements with Healthcare Professionals (HCPs), Healthcare Organizations (HCOs), Patients, Patient Advocacy Organizations (PAOs) and Payers.

Our suppliers and distributors are key contributors to the successful deployment of our products and services. Our offerings make a real difference in the lives of so many, and supply chain security and reliability are critical enablers for success. We work with our supply chain network to mitigate risks and ensure long-term viability. Our goal is to develop requirements across our supply chain to ensure suppliers and distributors act in an economically, environmentally, and socially responsible manner.

Communication with our suppliers and distributors takes place on a regular basis, through requests of proposals and requests for company overviews.

CareDx has implemented new supplier initiatives that will allow us to reduce transportation mileage and costs directly for the company or indirectly with new logistics providers for both testing services and lab products.

Our stockholders are some of our biggest supporters and continuous engagement is achieved through business updates via earnings calls, quarterly one-on-one meetings, and investor calls. We also participate in bank sponsored non-deal road shows, investor meetings, and conferences. CareDx also holds innovation days to highlight internal innovation and our external support for companies working to improve the lives of transplant patients. During the proxy season, CareDx also engages with top stockholders to gain insights and understand their views, priorities, and concerns around ESG topics.

We believe that engaging with our stockholders is fundamental to our commitment to good governance and is essential in aligning our corporate governance practices with evolving best practices. Throughout 2025, we connected with our institutional and individual investors and other stakeholders to share and receive feedback on our company's long-term growth strategy, quarterly earnings, and business announcements.

We strive to adopt a collaborative approach in these stockholder meetings to improve our understanding of the variety of perspectives and motivations of our investors.

CareDx regularly interacts with various government entities and is subject to a variety of laws and regulations. CareDx recognizes the importance of a robust compliance and ethics program.

Please see the CareDx Compliance and Ethics section of the corporate website for more information: https://caredx.com/company/caredx-corporate-compliance-and-ethics-program/

Additional stakeholder group engagement occurs through our medical and sales field channels (other than direct customers), professional outreach (including meetings, conference attendance and publications) and strategic partnerships (including those for bidding and proposal developments), steering committees, and advisory boards.

Communication channels for general outreach include media and reporters, public relations, press releases, media interviews, the general public, word of mouth, social media posts, media pickup, and special events (innovation days and investor days).

Communication channels for research-focused and professional outreach include professional meetings and events, conferences, publications, and email newsletters.

In the beginning of 2025, CareDx conducted a materiality assessment, evaluating various sustainability topics to determine their importance to the Company. The Company then benchmarked against industry peers to identify common material issues shared across the sector. CareDx has opted not to conduct a new materiality assessment in 2026, choosing instead to uphold the previously identified material topics. This approach allows the Company to allocate resources more effectively, track measurable progress, and engage more deeply with these topics. It also gives stakeholders greater visibility into long-term trends, reinforcing trust in the Company's ongoing commitment to its sustainability and strategic goals.

The following table outlines the material topics which had been identified as the most important.

5 9

15 17

Benchmarking

4 7

Low Importance Medium Importance

High Importance

1 Anti-corruption

2 Anti-competitive behavior

3 Compliance

4 Healthcare services and products

5 Customer health and safety

6 Employee health and safety

7 Training and education of employees

8 Diversity and equal opportunities

9 Non-discrimination

10 Products and services safety

11 Data privacy and cyber security

12 Employment

13 Corporate Governance

14 Energy consumption*

15 Greenhouse gas emissions*

16 Waste*

17 Support of local communities*

A list of the material topics and its prioritization is presented above.

The y-axis refers to the materiality of the issues from benchmarking and the x-axis refers to the materiality of the issues from CareDx.

CareDx receives feedback on ESG topics across our stakeholder groups, and this feedback is used to guide policy updates.

Access to healthcare services and products

Corporate Governance

Employee training and development

Anti-corruption

Customer health and safety

Employee health and safety

Anti-competitive behavior

Compliance (socio-economic

and environmental)

Data privacy/ cybersecurity

Diversity and

non-discrimination

Employment

Products and services safety

At CareDx, the protection of our local and global communities is critical to the long-term success of our customers and our company. We pursue the Triple Bottom Line or environmental and social profitability alongside financial profitability. Developing a holistic and long-term approach ensures our business activities have a wide-reaching impact across our community. Our sustainability/ESG initiatives align with eight of the 17 goals outlined in the 2030 United Nations Agenda for Sustainable Development: Goals 3, 4, 8, 9, 10, 12, 13

and 16.

Governance

A sound corporate governance is an essential part of our management and operations. The Board of Directors sets high standards for employees, officers, and directors.

It is the duty of the Board of Directors to serve as a prudent fiduciary for stockholders and to oversee the management of our business. To fulfill its responsibilities and to discharge its duties, the Board of Directors has adopted the procedures and standards that are set forth in the corporate governance guidelines. These guidelines are subject

to modification from time to time as the Board of Directors deems appropriate and in the best interests of the Company or as required by applicable laws and regulations. Visit

We believe strong governance starts with a diversity of experience, perspective, and opinions. Our Board of Directors is committed to optimizing its ability to effectively oversee and guide the Company by maintaining a diverse and well-rounded composition.

The following is an overview of the collective experiences, qualifications and attributes of our Board of Directors. Please see the sections titled "Directors with Terms Expiring at the Annual Meeting-Nominees for Director" and "Continuing Directors" in our definitive proxy statement for our 2026 annual meeting of stockholders filed with the SEC on April 27, 2026 for individual details regarding the experience and expertise of each of our directors.

10 OF 10

RELEVANT INDUSTRY KNOWLEDGE

8 OF 10

BUSINESS AND OPERATIONS LEADERSHIP EXPERIENCE

9 OF 10

INVESTMENT, FINANCE OR ACCOUNTING EXPERIENCE

9 OF 10

PUBLIC COMPANY BOARD OR GOVERNANCE EXPERIENCE

RISK MANAGEMENT

8 OF 10

M&A OR CORPORATE DEVELOPMENT EXPERIENCE

9 OF 10

REGULATORY AND LEGAL EXPERIENCE

FEMALE

2 OF 10

9 OF 10

INDEPENDENT

Defined policies ensure operations remain patient-centered, safe, and that business function is safeguarded. Copies of these documents are provided to applicable employees and partners across our organization. Employees and partners are also required to review and complete all appropriate required training associated with these policies.

+ Anti-Bribery and Anti-Corruption Policy

+ Chemical Hazards/Handling Policies

+ Code of Business Conduct and Ethics

+ Compliance and Ethics Program Corporate Governance Policy

+ Conflict of Interest Policy

+ Disaster Recovery and Business Continuity Plan

+ Due Diligence Screening of Proposed Candidates for Employment and Proposed Service Providers Policy

+ Employee Disciplinary Measures Policy

+ Interactions and Engagements with Healthcare Organizations (HCOs) Policy

+ Interactions and Engagements with Patients and Patient Advocacy Organizations

(PAOs) Policy

+ Interactions and Engagements with Payers Policy

+ Interactions and Engagements with Healthcare Professionals (HCPs) Policy

+ Internal Investigations Policy

+ IT Disaster Recovery Policy

+ Occupational Safety and Health Policies

+ Policy on the Review, Approval and Use of Materials and Messages Regarding CareDx Offerings

+ Specimen Collection Policy

CareDx's senior management and the Board of Directors review the risks on a regular basis and implement appropriate measures to address the risks. For example, the Company has identified cybersecurity as a risk. To minimize the risk, CareDx has hired top talent to lead the company's efforts to implement strong security policies, and conduct regular employee training, including tests to assess employee handling of potential phishing threats. The Company uses state of the art cybersecurity tools, encrypts sensitive data, uses multi-factor authentication, regularly updates software, and monitors network traffic.

Additionally, we have a Disaster Recovery (DR) and Business Continuity Plan (BCP) in place. The objective of the BCP is to provide guidance and strategy to management for the restoration of facilities and critical business processes. It is an essential requirement to provide ongoing AlloMap and AlloSure testing, test result reporting, and follow up to our external business partners to fund operations. The DR/BCP defines, at a high level, the recovery procedures required to continue/restore core services in the event of a disaster. This plan describes the organizational framework and procedures to be activated in the event of a disaster occurring, to enable recovery of services provided to patients and medical centers, including government agencies, the public, and all relevant business units supporting these services.

We recognize the importance of a robust Code of Business Conduct and Ethics. The CareDx Code includes the following:

Honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships.

Full, fair, accurate, timely, and understandable disclosure in reports and documents we file with or submit to the SEC and in our other public communications.

Compliance with applicable laws, rules and regulations.

Protection for persons reporting any behavior pursuant to the Code.

Accountability for adherence to the Code.

The Code applies to all directors, officers, and employees of CareDx, Inc. and its subsidiaries. Contractors, consultants, and other agents of the Company are also expected to read, understand and abide by the Code.

CareDx prohibits offering remuneration to foreign officials to influence the individual in their official capacity, to induce the individual to act in violation of their lawful duty or to secure any improper advantage to assist in obtaining or retaining business for or with, or direct business to, any person.

We do not have any legal actions against us regarding anti-competitive behavior.

Social Impact

Our mission is to create life-changing solutions that enable transplant patients to thrive. CareDx is an active and responsible member of the community in which we operate. Our social responsibility is expressed in many ways, such as our company-sponsored clinical trials and involvement in shaping public policy for transplant patients, providing education and training about important medical issues to patients and healthcare professionals,

CareDx is committed to disseminating information that educates transplant patients and their caregivers on relevant topical issues and post-transplant considerations.

CareDx is committed to helping patients with all aspects of testing, including financial assistance to those that qualify through CareDx's financial assistance program.

Based on the merits of the request, CareDx approves requests for financial support to nonprofit patient organizations that support the transplant community in increasing organ donor supply, education for patient pre- and post-transplant, and patient and caregiver support post-transplant.

CareDx invests in educational programs

to ensure adoption of the latest innovations to improve patient outcomes.

CareDx invested over $71.4 million in R&D

in 2025 to advance the next wave of innovation to improve patient outcomes.

CareDx provides financial support to defray societal costs for professional society meetings. Professional society meetings provide education and the latest advancements in transplantation.

CareDx presents the latest innovations at major professional society annual scientific meetings.

our involvement across the scientific community, and hosting or participating in medical conferences and symposiums. Over the previous year, CareDx was privileged to participate in a multitude of community-focused events highlighted below.

Patients and Patient Advocacy Groups

Healthcare Providers and Healthcare Organizations

CareDx provides research grants to drive the next wave of transplant innovation-for the betterment of science and long-term patient outcomes.

Employees

Local Communities

CareDx Living Donor Recovery Policy-Full-time employees are eligible to receive up to 30 days paid leave annually for donating an organ or up to 7 days for bone marrow transfer. For those who make the selfless act of donating an organ or bone marrow to help save another person's life, we want to ensure that our employees can do so without fear of wage loss or benefits.

CareDx employees provide support for state and local chapters of medical societies.

CareDx employees often participate as board members of patient association groups.

Employees are inspired by patients who are invited to share their journey at our

all-employee Town Hall meetings at CareDx.

We attend and help support local patient society advocacy fundraising (galas, walks) and local transplant organizations and patient support groups.

Field teams provide as-needed educational sessions, so healthcare providers understand our products and services and how to use reports to impact patient care.

Stem Cell Transplant Professionals

Lab Professionals

Transplant Administrators

Patients and Caregivers

Healthcare Professionals

On our website, we offer a multitude of resources (webinars, publications/abstracts, documents/brochures and videos) for:

CareDx prioritizes participation in clinical, scientific, and system-level forums where engagement directly supports patient outcomes, ethical standards, and the integrity of care delivery. These meetings reflect our commitment to evidence-based medicine, equity in access, scientific rigor, and long-term healthcare sustainability.

+ American Society for Histocompatibility and Immunogenetics (ASHI)

+ American Society of Transplantation Cutting Edge of Transplantation (CEoT)

+ American Society of Transplant Surgeons Winter Symposium (ASTS)

+ American Transplant Congress: Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation (ATC)

+ European Immunogenetics and Histocompatibility Conference (EFI)

+ Heart Failure Society of America Annual Scientific Meeting (HFSA)

+ International Society for Heart and Lung Transplantation Annual Meeting and Scientific Sessions (ISHLT)

+ Tandem Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research (TANDEM)

+ United Network for Organ Sharing Transplant Management Forum (UNOS)

+ American Society of Nephrology (ASN)

+European Society for Organ Transplantation Congress (ESOT)

+ NATCO: The Organization for Transplant Professionals (NATCO)

+ The Alliance (The Alliance)

+ American Liver and Multivisceral Transplantation Organization Meeting (ALAMO)

Conference Participation (2025) Highlights

Clinical trials may provide the ability for a patient to gain access to new treatments before they become available to all, thus contributing to scientific research and to the improved management of medical conditions. Clinical trials are subject to national and international standards and guidelines.

ACROBAT is a multicenter, prospective, observational registry designed to assess chimerism and relapse post-bone marrow/hematopoietic cell transplant (HCT) of recipients managed with AlloHeme.

ALAMO is a multicenter, prospective, observational registry designed to evaluate outcomes of lung transplant recipients managed with AlloSure Lung and AlloMap Lung.

KOAR is a multicenter, prospective, observational registry designed to evaluate outcomes of kidney transplant recipients managed with AlloSure Kidney.

MAPLE is a multicenter, prospective, observational registry designed to evaluate outcomes of liver transplant recipients managed with AlloSure Liver and AlloMap Liver.

OKRA is a multicenter, prospective, observational registry designed to evaluate outcomes of kidney transplant recipients managed with AlloSure Kidney and AlloMap Kidney.

SHORE is a multicenter, prospective, observational registry designed to evaluate outcomes of heart transplant recipients managed with HeartCare.

Support of Clinical Trials and Studies (2025) 20

Disclaimer

CareDx Inc. published this content on April 29, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 29, 2026 at 15:55 UTC.